DAA Best Practice Guidelines for the Treatment of Overweight and Obesity in Adults

Overweight and obesity are complex, chronic conditions that increase the risk of a wide range of noncommunicable diseases, including type 2 diabetes, cardiovascular disease, certain cancers, and osteoarthritis. The Diabetes Association of America (DAA) has issued comprehensive, evidencebased recommendations to help clinicians deliver consistent, patientcentred care. The guidelines stress a combination of lifestyle modification, pharmacotherapy, and when appropriate, metabolicbariatric surgery.

1. Scope and Definitions

Overweight: Body mass index (BMI) 25.029.9kg/m.
Obesity: BMI30kg/m; further classified as ClassI (3034.9), ClassII (3539.9), and ClassIII (40).
Abdominal obesity: Waist circumference >102cm (men) or >88cm (women).
The guidelines apply to adults 18years, across all ethnicities, and are intended for use in primary care, specialty clinics, and community health settings.

2. Initial Assessment

2.1 Clinical Evaluation

• Measure weight, height, BMI, waist circumference, and blood pressure.
• Obtain a detailed medical, medication, and psychosocial history.
• Screen for obesityrelated comorbidities (e.g., dyslipidaemia, hypertension, sleep apnea, NAFLD, infertility).
• Assess readiness to change using the Stages of Change model.

2.2 Laboratory Tests

• Fasting plasma glucose or HbA1c.
• Lipid profile.
• Liver enzymes, creatinine, and eGFR.
• Thyroidstimulating hormone if indicated.

3. Lifestyle Intervention The Foundation of Care

3.1 Dietary Therapy

• Adopt an energydeficit diet of 500750kcal/day below estimated needs.
• Prioritise nutrientdense foods: vegetables, fruits, whole grains, lean protein, and healthy fats.
• Consider structured approaches such as the Mediterranean diet, DASH, or lowcarbohydrate plans based on patient preference.
• Use portioncontrol tools and foodlogging apps to enhance adherence.

3.2 Physical Activity

• Goal: 150minutes/week of moderateintensity aerobic activity (e.g., brisk walking) plus two sessions of resistance training.
• Encourage incorporation of activity into daily routines (stairs, active transport).
• Tailor intensity to fitness level and comorbid conditions.

3.3 Behavioural Strategies

• Motivational interviewing to explore ambivalence.
• Cognitivebehavioral techniques for selfmonitoring, goalsetting, and problem solving.
• Regular followup (monthly for the first six months) to reinforce progress.

4. Pharmacotherapy

Medication is recommended when:

• BMI30kg/m, or BMI27kg/m with at least one weightrelated comorbidity, and lifestyle measures have failed after a minimum of 36months of intensive intervention.
• Patient is motivated, has no contraindications, and understands potential side effects.

4.1 Approved Agents (US FDA/EMA)

• Orlistat lipase inhibitor; 120mg TID with meals; modest weight loss (35%); watch for GI sideeffects and fatsoluble vitamin deficiency.
• GLP1 receptor agonists liraglutide 3.0mg daily, semaglutide 2.4mg weekly; 1015% weight loss; monitor for nausea, pancreatitis risk.
• Combination therapy phentermine/topiramate extendedrelease; naltrexone/bupropion; require careful blood pressure and psychiatric screening.
• Emerging agents tirzepatide (dual GIP/GLP1) shows promising 1520% reductions, pending final guideline inclusion.

4.2 Monitoring

• Baseline vitals, labs, and BMI.
• Reevaluate at 12 weeks; discontinue if <5% weight loss achieved without adverse events.
• Longterm followup for safety (e.g., cardiovascular outcomes, mental health).

5. MetabolicBariatric Surgery (MBS)

Indicated for:

• BMI40kg/m, or BMI35kg/m with a serious obesityrelated disease.
• BMI30kg/m with uncontrolled type 2 diabetes or metabolic syndrome when other options have failed.

5.1 Types of Procedures

• Sleeve gastrectomy most common; 2535% excess weight loss.
• RouxenY gastric bypass higher weight loss, greater impact on glucose metabolism.
• Adjustable gastric band and biliopancreatic diversion are reserved for select cases.

5.2 Preoperative Evaluation

• Multidisciplinary assessment (surgery, nutrition, psychology, endocrinology).
• Optimization of comorbidities and cessation of smoking.

5.3 Postoperative Care

• Lifelong dietary counseling and vitamin supplementation (B12, iron, calcium, vitamin D).
• Regular surveillance for complications (e.g., anastomotic ulcer, dumping syndrome).
• Continued weightmaintenance support to prevent regain.

6. Special Populations

• Older adults (65years) gentler calorie deficit, focus on protein intake and fallprevention exercise; assess frailty before pharmacotherapy.
• Pregnant or lactating women weightloss drugs are contraindicated; emphasize healthy gestational weight gain and postpartum counseling.
• Patients with mental health disorders coordinate with psychiatry; avoid medications with known psychiatric sideeffects.

7. FollowUp and LongTerm Management

Weight management is a chronic condition. The DAA recommends:

• Quarterly visits during the first year, then semiannual or annual thereafter.
• Continuous reinforcement of lifestyle habits, regardless of weightloss method.
• Use of digital tools (telehealth, mobile apps) to improve adherence.
• Reassessment of comorbidities and medication adjustments as needed.

8. Implementation Tools for Clinicians

• Decisionmaking algorithm short flowchart integrating BMI, comorbidities, and prior treatment response.
• Patienthandout templates clear explanations of each therapy, expected benefits, and sideeffects.
• Electronic health record (EHR) prompts alerts for annual obesity assessment and medication review.

9. Summary of Key Recommendations

1. Screen every adult for BMI and waist circumference at least annually.
2. Begin with intensive, structured lifestyle intervention; aim for 5% weight loss in 36months.
3. Add pharmacotherapy when BMI thresholds are met and lifestyle alone is insufficient.
4. Consider metabolicbariatric surgery for severe obesity or obesity with uncontrolled metabolic disease.
5. Provide lifelong followup, emphasising maintenance of weight loss and monitoring of comorbidities.

These guidelines are designed to be adaptable across diverse practice settings while maintaining a high standard of evidencebased care. By integrating assessment, lifestyle modification, pharmacologic options, and surgical pathways, clinicians can offer a personalized, comprehensive strategy to combat overweight and obesity in adults.

For the full guideline document, implementation resources, and patient education materials, visit the DAA official website.